Head and Neck Neurologic Complications of Malignancy

  • N. Simon Tchekmedyian
  • Richard S. Kaplan
Part of the Developments in Oncology book series (DION, volume 36)


Neurologic complications of malignancy in the head and neck region may result from direct tumor invasion of neural structures or adjacent tissues or from the effects of systemic cancer. Complications may also be related to the various treatment modalities used in the management of both systemic cancer and cancer involving the nervous system. This discussion is divided into two sections: (a) complications affecting mainly the brain, resulting from malignant invasion, thrombocytopenia and coagulopathy, hypercalcemia, and toxicity of therapy; and (b) complications affecting mainly the meninges and cranial nerves, resulting from malignant invasion and its management. Cerebrovascular complications in patients with cancer have been recently reviewed in detail [1] and are not directly addressed here.


Brain Metastasis Acute Lymphoblastic Leukemia Acute Leukemia Disseminate Intravascular Coagulation Cranial Irradiation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Graus F, Rogers LR, Posner JB: Cerebrovascular complications in patients with cancer. Medicine 64:16–35, 1985.PubMedGoogle Scholar
  2. 2.
    Pickren JW, Lopez G, Tsukada Y, Lane WW: Brain metastases: an autopsy study. Cancer Treat Rep 2:295–313, 1983.Google Scholar
  3. 3.
    Posner JB, Chernik NL: Intracranial metastases from systemic cancer. Adv Neurol 19:575–587, 1978.Google Scholar
  4. 4.
    Borgelt B, Gelber R, Kramer S, et al.: The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6:1–13, 1980.PubMedGoogle Scholar
  5. 5.
    Van Hazel GA, Scott M, Eagan RT: The effect of CNS metastases on the survival of patients with small cell cancer of the lung. Cancer 51:933–937, 1983.PubMedGoogle Scholar
  6. 6.
    Komaki R, Cox JD, Stark R: Frequency of brain metastasis in adenocarcinoma and large cell carcinoma of the lung: correlation with survival. Int J Radiat Oncol Biol Phys 9:1467–1470, 1983.PubMedGoogle Scholar
  7. 7.
    Madajewicz S, Karakousis C, West CR, Caracandas J, Avellanosa AM: Malignant melanoma brain metastases. Cancer 53:2550–2552, 1984.PubMedGoogle Scholar
  8. 8.
    Aroney RS, Aisner J, Wesley MN, et al.: Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma. Cancer Treat Rep 67:675–682, 1983.PubMedGoogle Scholar
  9. 9.
    Chason JL, Walker FB, Landers JW: Metastatic carcinoma in the central nervous system and dorsal root ganglia: a prospective autopsy study. Cancer 16:781–787, 1963.PubMedGoogle Scholar
  10. 10.
    Amer MH, Al-Sarraf Muhyi, Baker LH, Vait-kevicius VK: Malignant melanoma and central nervous system metastases. Cancer 42:660–668, 1978.PubMedGoogle Scholar
  11. 11.
    Brunson KV, Beattie G, Nicolson GL: Selection and altered properties of brain-colonising metastatic melanoma. Nature 272:543–545, 1978.PubMedGoogle Scholar
  12. 12.
    Gercovich FG, Luna MA, Gottlieb JA: Increased incidence of cerebral matastases in sarcoma patients with prolonged survival from chemotherapy. Cancer 36:1843–1851, 1975.PubMedGoogle Scholar
  13. 13.
    Mayer RJ, Berkowitz RS, Griffiths CT: Central nervous system involvement by ovarian carcinoma: a complication of prolonged survival with metastatic disease. Cancer 41:776–783, 1978.PubMedGoogle Scholar
  14. 14.
    Byrne TN, Cascino TL, Posner JB: Brain metastasis from melanoma. J Neurncol 1:313–317, 1983.Google Scholar
  15. 15.
    Frei E III: Acute leukemia in children. Cancer 53:2013–2025, 1984.PubMedGoogle Scholar
  16. 16.
    Posner JB: Brain metastases: a clinician’s view. In: Weiss L, Gilbert HA, Posner JB (eds) Brain metastasis. Boston, GK Hall, 1980.Google Scholar
  17. 17.
    Hayman LA, Evans RA, Hinck VC: Delayed high iodine dose contrast computed tomography: cranial neoplasms. Radiology 136:677–684, 1980.PubMedGoogle Scholar
  18. 18.
    Messina AV: Cranial computerized tomography: a radiologie-pathologie correlation. Arch Neurol 34:602–607, 1977.PubMedGoogle Scholar
  19. 19.
    Mehta I, Khatib R, Patel S: Carcinoma of the breast and meningioma: association and management. Cancer 51:1937–1940, 1983.PubMedGoogle Scholar
  20. 20.
    Scott WR: Seizures: a reaction to contrast media for computed tomography of the brain. Radiology 137:359–361, 1980.PubMedGoogle Scholar
  21. 21.
    Letter to the editor: Convulsions: a complication of contrast enhancement in computerized tomography. Arch Neurol 34:649–650, 1977.Google Scholar
  22. 22.
    Pagani JJ, Hayman LA, Bigelow RH, Libshitz HI, Lepke RA, Wallace S: Diazepam prophylaxis of contrast media-induced seizures during computed tomography of patients with brain metastases. AJR 140:787–792, 1983.PubMedGoogle Scholar
  23. 23.
    Rosner D, Nemoto T: Blood-brain barrier a myth? Chemotherapy of central nervous system (CNS) metastases in breast cancer: a pilot study. Proc Am Assoc Cancer Res 24:553, 1983.Google Scholar
  24. 24.
    Stewart DJ, Richard M, Hugenholtz H, Dennery J: VP-16 (VP) and VM-26 (VM) penetration into human brain tumors (BT). Proc Am Assoc Cancer Res 24:527, 1983.Google Scholar
  25. 25.
    Hasegawa H, Ushio Y, Hayakawa T, Yamada K, Mogami H: Changes of the blood-brain barrier in experimental metastatic brain tumors. J Neurosurg 59:304–310, 1983.PubMedGoogle Scholar
  26. 26.
    Ehrenkranz JR, Posner JB: Adrenocorticoste-roid hormones. In: Weiss L, Gilbert HA, Posner JB (eds) Brain metastasis. Boston, GK Hall, 1980.Google Scholar
  27. 27.
    Gamache FW Jr, Galicich JH, Posner JB: Treatment of brain metastases by surgical extirpation. In: Weiss L, Gilbert HA, Posner JB (eds) Brain metastasis. Boston, GK Hall, 1980.Google Scholar
  28. 28.
    Hendrickson FR, Lee M-S, Larson M, Gelber RD: The influence of surgery and radiation therapy of patients with brain metastases. Int J Radiat Oncol Biol Phys 9:623–627, 1983.PubMedGoogle Scholar
  29. 29.
    Decker DA, Decker VL, Herskovic A, Cum-mings GD: Brain metastases in patients with renal cell carcinoma: prognosis and treatment. J Clin Oncol 2:169–173, 1984.PubMedGoogle Scholar
  30. 30.
    Sundaresan N, Galicich JH, Beattie EJ: Surgical treatment of brain metastases from lung cancer. J Neurosurg 58:666–671, 1978.Google Scholar
  31. 31.
    Chan RC, Steinbok P: Solitary cerebral metastasis: the effect of craniotomy on the quality and the duration of survival. Neurosurgery 11:254–257, 1982.PubMedGoogle Scholar
  32. 32.
    Gagliardi FM, Mercuri S: Single metastases in the brain: late results in 325 cases. Acta Neurochirug 68:253–262, 1983.Google Scholar
  33. 33.
    Borgelt B, Gelber R, Kramer S, et al.: The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 60:1–13, 1980.Google Scholar
  34. 34.
    Weed JC, Woodward KT, Hammond CH: Choriocarcinoma metastatic to the brain: therapy and prognosis. Semin Oncol 9:208–212, 1982.PubMedGoogle Scholar
  35. 35.
    Lester SG, Morphis JG II, Hornback NB, Williams SD, Einhorn LH: Brain metastases and testicular tumors: need for aggressive therapy. J Clin Oncol 2:1397–1403, 1984.PubMedGoogle Scholar
  36. 36.
    Neiman RS, Barcos M, Berard C, et al.: Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases. Cancer 48:1426–1437, 1981.PubMedGoogle Scholar
  37. 37.
    Wiernik PH, Serpick AA: Granulocytic sarcoma (chloroma). Blood 35:361–369, 1970.PubMedGoogle Scholar
  38. 38.
    Muss HB, Moloney WC: Chloroma and other myeloblastic tumors. Blood 42:721–728, 1973.PubMedGoogle Scholar
  39. 39.
    Vinters HV, Gilbert JJ: Multifocal chloromas of the brain. Surg Neurol 17:47–51, 1982.PubMedGoogle Scholar
  40. 40.
    Krishnamurthy M, Nusbacher N, Elguezabal A, Seligman BR: Granulocytic sarcoma of the brain. Cancer 39:1542–1546, 1977.PubMedGoogle Scholar
  41. 41.
    Demaray MJ, Coladonato JP, Parker JC, Roso-moff HL: Intracerebellar chloroma (granulocytic sarcoma): a neurosurgical complication of acute myelocytic leukemia. Surg Neurol 6:353–356, 1976.PubMedGoogle Scholar
  42. 42.
    Hurwitz BS, Sutherland JC, Walker MD: Central nervous system chloromas preceding acute leukemia by one year. Neurology 20:771–775, 1970.PubMedGoogle Scholar
  43. 43.
    Russo A, Azzia N, Genovese, R, Ramella M: A case of chloroma. Pediatria (Napoli) 91:65–70, 1983.Google Scholar
  44. 44.
    Sowers JJ, Moody DM, Naidich TP, Ball MR, Laster DW, Leeds NE: Radiographic features of granulocytic sarcoma (chloroma). J Comput Assist Tomogr 3:226–233, 1979.PubMedGoogle Scholar
  45. 45.
    Nickels J, Koivuniemi A, Heiskanen O: Granulocytic sarcoma (chloroma) of the cerebellum and meninges: a case report. Acta Neurochirug 46:297–301, 1979.Google Scholar
  46. 46.
    Krause JR: Granulocytic sarcoma preceding acute leukemia: a report of six cases. Cancer 44:1017–1021, 1979.PubMedGoogle Scholar
  47. 47.
    Freireich EJ, Thomas LB, Frei E, Fritz RD, Forkner CE: A distinctive type of intracerebral hemorrhage associated with “blastic crisis” in patients with leukemia. Cancer 13:146–154, 1960.PubMedGoogle Scholar
  48. 48.
    McKee LC, Collins RD: Intravascular leukocyte thrombi and aggregates as a cause of morbidity and mortality in leukemia. Medicine 53:463–478, 1974.PubMedGoogle Scholar
  49. 49.
    Hug V, Keating M, McCredie K, Hester J, Bodey GP, Freireich EJ: Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count. Cancer 52:773–779, 1983.PubMedGoogle Scholar
  50. 50.
    Wald BR, Heisel MA, Ortega JA: Frequency of early death in children with acute leukemia presenting with hyperleukocytosis. Cancer 50:150–153, 1982.PubMedGoogle Scholar
  51. 51.
    Dearth JC, Fountain KS, Smithson WA, Burgert EO, Gilchrist GS: Extreme leukemic leukocytosis (blast crisis) in childhood. Mayo Clin Proc 53:207–211, 1978.PubMedGoogle Scholar
  52. 52.
    Rowe JM, Lichtman MA: Hyperleukocytosis and leukostasis: common features of childhood chronic myelogenous leukemia. Blood 63:1230–1234, 1984.PubMedGoogle Scholar
  53. 53.
    Wiernik PH, Serpick AA: Factors affecting remission and survival in adult acute nonlymph-ocytic leukemia (ANLL). Medicine 49:505–513, 1970.PubMedGoogle Scholar
  54. 54.
    Wiernik PH: Management of the acute leukemia patient. Conn Med 39:681–685, 1975.PubMedGoogle Scholar
  55. 55.
    Gilchrist GS, Fountain KS, Dearth JC, Smith-son WA, Burgert O: Cranial irradiation in the management of extreme leukemic leukocytosis complicating childhood acute lymphocytic leukemia. J Pediatr 98:257–259, 1981.PubMedGoogle Scholar
  56. 56.
    Poussin-Rosillo H, Strohl R, Kaplan R, Slaw-son RG, Salazar OM: Radiation therapy for the prevention of cerebral hemorrhage in patients with adult leukemia presenting with hyperleukocytosis and blast crisis. Int J Rad Oncol Biol Phys 9 (Suppl 1):139, 1983.Google Scholar
  57. 57.
    Harris AL: Leukostasis associated with blood transfusion in acute myeloid leukemia. Br Med J 1:1169–1171, 1978.PubMedGoogle Scholar
  58. 58.
    Lichtman MA, Rowe JM: Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations. Blood 60:279–283, 1982.PubMedGoogle Scholar
  59. 59.
    Hersh EM, Bodey GP, Nies BA, Freireich EJ: Causes of death in acute leukemia: a ten-year study of 414 patients from 1954–1963. JAMA 193:105–109, 1965.PubMedGoogle Scholar
  60. 60.
    Ivy AC, Nelson D, Bucher G: The standardization of certain factors in the cutaneous “veno-stasis” bleeding time technique. J Clin Med 26:1812–1822, 1941.Google Scholar
  61. 61.
    Harker LA, Slichter SJ: The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 287:155–159, 1972.PubMedGoogle Scholar
  62. 62.
    Gaydos LA, Freireich EJ, Mantel N: The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 266:905–909, 1962.PubMedGoogle Scholar
  63. 63.
    Belt RJ, Leite C, Haas CD, Stephens RL: Incidence of hemorrhagic complications in patients with cancer. JAMA 239:2571–2574, 1978.PubMedGoogle Scholar
  64. 64.
    Cohen P, Gardner FH: Thrombocytopenia as a laboratory sign and complication of gram-negative bacteremic infection. Arch Intern Med. 117:113–124, 1966.PubMedGoogle Scholar
  65. 65.
    Seifter EJ, Bell WR: Coagulation abnormalities in patients with cancer. Clin Oncol 2:657–704, 1983.Google Scholar
  66. 66.
    Neame PB, Kelton JG, Walker IR, Stewart IO, Nossel HL, Hirsh J: Thrombocytopenia in septicemia: the role of disseminated intravascular coagulation. Blood 56:88–92, 1980.PubMedGoogle Scholar
  67. 67.
    Schafer AI: Bleeding and thrombosis in the myeloproliferative disorders. Blood 64:1–12, 1984.PubMedGoogle Scholar
  68. 68.
    Dutcher JP, Schiffer CA, Aisner J, et al.: Incidence of thrombocytopenia and serious hemorrhage among patients with solid tumors. Cancer 53:557–562, 1984.PubMedGoogle Scholar
  69. 69.
    Rubenstein RA, Yanoff M, Albert DM: Thrombocytopenia, anemia and retinal hemorrhage. Am J Ophthalmol 65:435–439, 1968.PubMedGoogle Scholar
  70. 70.
    Higby DJ, Cohen E, Holland JF, Sinks L: The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion 14:440–446, 1974.PubMedGoogle Scholar
  71. 71.
    Roy AJ, Jaffe N, Djerassi I: Prophylactic platelet transfusions in children with acute leukemia: a dose response study. Transfusion 13:283–290, 1973.PubMedGoogle Scholar
  72. 72.
    Han T, Stutzman L, Cohen E, Kim U: Effect of platelet transfusion on hemorrhage in patients with acute leukemia: an autopsy study. Cancer 19:1937–1942, 1966.PubMedGoogle Scholar
  73. 73.
    Dutcher JP, Schiffer CA: Platelet and granulocyte transfusion therapy. In: Wiernik PH (ed) Supportive care of the cancer patient. New York, Futura, 1983, pp 109–143.Google Scholar
  74. 74.
    Bender RA, Hansen H: Hypercalcemia in bronchogenic carcinoma: a prospective study of 200 patients. Ann Intern Med 80:205–208, 1974.PubMedGoogle Scholar
  75. 75.
    Stephens RL, Hansen HH, Muggia FM: Hypercalcemia in epidermoid tumors of the head and neck and esophagus. Cancer 31:1487–1491, 1973.PubMedGoogle Scholar
  76. 76.
    Won C, Decker DA, Drelichman A, Al-Sarraf M, Reed ML: Hypercalcemia in head and neck carcinoma. Cancer 52:2261–2263, 1983.PubMedGoogle Scholar
  77. 77.
    Bunn PA, Schechter GP, Jaffe E, et al.: Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med 309:257–264, 1983.PubMedGoogle Scholar
  78. 78.
    Blayney DW, Jaffe ES, Fisher RI, et al.: The human T-cell leukemia/lymphoma virus, lymphoma, lytic bone lesions, and hypercalcemia. Ann Intern Med 98:144–151, 1983.PubMedGoogle Scholar
  79. 79.
    Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE: Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 291:1041–1046, 1974.PubMedGoogle Scholar
  80. 80.
    Mundy GR, Luben RA, Raisz LG, Oppenheim JJ, Buell DN: Bone-resorbing activity in super-natants from lymphoid cell lines. N Engl J Med 290:867–871, 1974.PubMedGoogle Scholar
  81. 81.
    Mundy GR, Ibbotson KJ, D’Souza SM, Simpson EL, Jacobs JW, Martin TJ: The hypercalcemia of cancer: clinical implications and pathogenic mechanisms. N Engl J Med 310:1718–1736, 1984.PubMedGoogle Scholar
  82. 82.
    Annesley TM, Burritt MF, Kyle RA: Artifac-tual hypercalcemia in multiple myeloma. Mayo Clin Proc 57:572–575, 1982.PubMedGoogle Scholar
  83. 83.
    Zeffren JL, Heinemann HO: Reversible defect in renal concentrating mechanism in patients with hypercalcemia. Am J Med 33:54–63, 1962.PubMedGoogle Scholar
  84. 84.
    Suki WN, Yium JJ, Von Minden M, et al.: Acute treatment of hypercalcemia with furosemide. N Engl J Med 283:836–840, 1970.PubMedGoogle Scholar
  85. 85.
    Miach PJ, Dawborn JK, Martin TJ, Moon WJ: Management of the hypercalcemia of malignan-cy by peritoneal dialysis. Med J Aust 1:782–784, 1975.PubMedGoogle Scholar
  86. 86.
    Strauch BS, Ball MF: Hemodialysis in the treatment of severe hypercalcemia. JAMA 235:1347–1348, 1976.PubMedGoogle Scholar
  87. 87.
    Austin LA, Heath H: Calcitonin: physiology and pathophysiology. N Engl J Med 304:269–278, 1981.PubMedGoogle Scholar
  88. 88.
    Kiang DT, Loken MK, Kennedy BJ: Mechanism of the hypocalcemic effect of mithramycin. J Clin Endocrinol Metab 48:341–344, 1979.PubMedGoogle Scholar
  89. 89.
    Perlia CP, Gubisch NJ, Wolter J, Edelberg D, Dederick MM, Taylor SG: Mithramycin treatment of hypercalcemia. Cancer 25:389–394, 1970.PubMedGoogle Scholar
  90. 90.
    Kennedy BJ: Metabolic and toxic effects of mithramycin during tumor therapy. Am J Med 49:494–503, 1970.PubMedGoogle Scholar
  91. 91.
    Lazor MZ, Rosenberg LE: Mechanism of adrenal-steroid reversal of hypercalcemia in multiple myeloma. N Engl J Med 270:749–755, 1964.PubMedGoogle Scholar
  92. 92.
    Bentzel CJ, Carbone PP, Rosenberg L: The effect of prednisone on calcium metabolism and Ca 47 kinetics in patients with multiple myeloma and hypercalcemia. J Clin Invest 43:2132–2145, 1964.PubMedGoogle Scholar
  93. 93.
    Strumpf M, Kowalski MA, Mundy GR: Effects of glucocorticoids on osteoclast-activating factor. J Lab Clin Med 92:772–778, 1978.PubMedGoogle Scholar
  94. 94.
    Myers WPL: Cortisone in the treatment of hypercalcemia in neoplastic disease. Cancer 11:83–88, 1958.PubMedGoogle Scholar
  95. 95.
    Mannheimer IH: Hypercalcemia of breast cancer: management with corticosteroids. Cancer 18:679–691, 1965.PubMedGoogle Scholar
  96. 96.
    Thalassinos NC, Joplin GF: Failure of corticosteroid therapy to correct the hypercalcaemia of malignant disease. Lancet 1:537–538, 1970.Google Scholar
  97. 97.
    Tashjian AH: Prostaglandins, hypercalcemia and cancer. N Engl J Med 293:1317–1318, 1975.PubMedGoogle Scholar
  98. 98.
    Kaplan RS, Wiernik PW: Neurotoxicity of antitumor agents. In: Perry MC, Yabro JW (eds) Toxicity of chemotherapy. New York: Grune and Stratton, 1984.Google Scholar
  99. 99.
    Duttera MJ, Bleyer WA, Pomeroy TC, et al.: Irradiation, methotrexate toxicity, and the treatment of meningeal leukemia. Lancet 2:703–707, 1973.PubMedGoogle Scholar
  100. 100.
    Bleyer WA, Drake JC, Chabner BA: Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 289:770–773, 1973.PubMedGoogle Scholar
  101. 101.
    Sullivan MP, Vietti TJ, Fernbach DJ, et al.: Clinical investigations in the treatment of meningeal leukemia: radiation therapy regimens vs. conventional intrathecal methotrexate. Blood 34:301–319, 1969.PubMedGoogle Scholar
  102. 102.
    Naiman JL, Rupprecht LM, Tanyeri G, et al.: Intrathecal methotrexate. Lancet 1:571, 1970.PubMedGoogle Scholar
  103. 103.
    Hutchison JH (Chairman, Working Party): Treatment of acute lymphoblastic leukemia: comparison of immunotherapy (BCG), intermittent methotrexate, and no therapy after a five-month intensive cytotoxic regimen (Concord trial). Br Med J 4:189–194, 1971.Google Scholar
  104. 104.
    Mott MG, Stevenson P, Wood CBC: Methotrexate meningitis. Lancet 2:656, 1972.PubMedGoogle Scholar
  105. 105.
    Aur RJA, Hustu HO, Verzosa MS, et al.: Comparison of two methods of preventing central nervous system leukemia. Blood 42:349–357, 1973.PubMedGoogle Scholar
  106. 106.
    Geiser CF, Bishop Y, Jaffe N, et al.: Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood 45:189–195, 1975.PubMedGoogle Scholar
  107. 107.
    Trump D, Grossman, S Thompson G, et al.: Treatment of neoplastic meningitis with intrathecal methotrexate and Thiotepa. Proc Am Assoc Cancer Res 22:160, 1981.Google Scholar
  108. 108.
    Skullerud K, Halvorsen K: Encephalomyelo-pathy following intrathecal methotrexate treatment in a child with acute leukemia. Cancer 42:1211–1215, 1978.PubMedGoogle Scholar
  109. 109.
    Saiki JH, Thompson S, Smith F, Atkinson R: Paraplegia following intrathecal chemotherapy. Cancer 29:370–374, 1972.PubMedGoogle Scholar
  110. 110.
    Gagliano RG, Costanzi JJ: Paraplegia following intrathecal methotrexate. Cancer 37:1663–1668, 1976.PubMedGoogle Scholar
  111. 111.
    Gutin PH, Levi J A, Wiernik PH, Walker MD: Treatment of malignant meningeal disease with intrathecal Thiotepa: a phase II study. Cancer Treat Rep 61:885–887, 1977.PubMedGoogle Scholar
  112. 112.
    Bleyer WA, Drake JC, Chabner BA: Methotrexate neurotoxicity. N Engl J Med 290:57, 1974.Google Scholar
  113. 113.
    Shapiro WR, Chernik NL, Posner JB: Necrotizing encephalopathy following intraventricular instillation of methotrexate. Arch Neurol 28:96–102, 1973.PubMedGoogle Scholar
  114. 114.
    Bleyer WA, Dedrick RL: Clinical pharmacology of intrathecal methotrexate. L Pharmacokinetics in non-toxic patients after lumbar injection. Cancer Treat Rep 61:703–708, 1977.PubMedGoogle Scholar
  115. 115.
    Grossman SA, Trump DL, Chen DC, Thompson G, Camargo EE: Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis: an evaluation using 111indium-DTPA ventriculography. Am J Med 73:641–647, 1982.PubMedGoogle Scholar
  116. 116.
    Shapiro WR, Young DF, Mehta BM: Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293:161–166, 1975.PubMedGoogle Scholar
  117. 117.
    Norrell H, Wilson CB, Slagel DE, Clark DB: Leukoencephalopathy following the administration of methotrexate into the cerebrospinal fluid in the treatment of primary brain tumors. Cancer 33:923–932, 1974.PubMedGoogle Scholar
  118. 118.
    Blasberg RG, Patlak CS, Shapiro WR: Distribution of methotrexate in the cerebrospinal fluid and brain after ventricular administration. Cancer Treat Rep 61:633–641, 1977.PubMedGoogle Scholar
  119. 119.
    Allen JC, Rosen G: Transient cerebral dysfunction following chemotherapy for osteogenic sarcoma. Ann Neurol 3:441–444, 1978.PubMedGoogle Scholar
  120. 120.
    Eden OB, Goldie W, Wood T, Etcubanas E: Seizures following intrathecal cytosine arabino-side in young children with acute lymphoblastic leukemia. Cancer 42:53–58, 1978.PubMedGoogle Scholar
  121. 121.
    Dieterich E: Encephalopathy due to vincristine sulfate. Kin Paediatr 191:145–147, 1979.Google Scholar
  122. 122.
    Slater LM, Wainer RA, Serpick AA: Vincristine neurotoxicity with hyponatremia. Cancer 23:122–125, 1969.PubMedGoogle Scholar
  123. 123.
    Suskind RM, Brusilow SW, Zehr J: Syndrome of inappropriate secretion of antidiurectic hormone produced by vincristine toxicity (with bioassay of ADH level). J Pediatr 81:90–92, 1972.PubMedGoogle Scholar
  124. 124.
    Whittaker JA, Parry DH, Bunch C, Weatherall DJ: Coma associated with vincristine therapy. Br Med J 4:335–337, 1973.PubMedGoogle Scholar
  125. 125.
    Cutting HO: Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy. Am J Med 51:269–271, 1971.PubMedGoogle Scholar
  126. 126.
    Robertson GL, Bhoopalam N, Zelkowitz LJ: Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone. Arch Intern Med 132:717–720, 1973.PubMedGoogle Scholar
  127. 127.
    Stuart MJ, Cuaso C, Miller M, Oski FA: Syndrome of recurrent increased secretion of antidiuretic hormone following multiple doses of vincristine. Blood 45:315–320, 1975.PubMedGoogle Scholar
  128. 128.
    Ginsberg SJ, Comis RL, Fitzpatrick AV: Vinblastine and inappropriate ADH secretion. N Engl J Med 296:941, 1977.PubMedGoogle Scholar
  129. 129.
    Kaplan SL, Feigin RD: Syndromes of inappropriate secretion of antidiuretic hormone in children. Adv Pediatr 27:247–274, 1980.PubMedGoogle Scholar
  130. 130.
    Harlow PJ, De Clerck YA, Shore NA, et al.: A fatal case of inappropriate ADH secretion induced by cyclophosphamide therapy. Cancer 44:896–898, 1979.PubMedGoogle Scholar
  131. 131.
    Kaufman I A, Kung FH, Koenig HM, Giammo-na ST: Overdosage with vincristine. J Pediatr 89:671–674, 1976.PubMedGoogle Scholar
  132. 132.
    Schocher SS, Lampert PW, Earle KM: Neuronal changes induced by intrathecal vincristine sulfate. J Neuropathol Exp Neurol 27:645–658, 1968.Google Scholar
  133. 133.
    Shepherd DA, Steuber CP, Starling KA, Fern-bach DJ: Accidental intrathecal administration of vincristine. Med Pediatr Oncol 5:85–88, 1978.PubMedGoogle Scholar
  134. 134.
    Slyter H, Liwnicz B, Herrick MK, Mason R: Fatal myeloencephalopathy caused by intrathecal vincristine. Neurology 30:867–871, 1980.PubMedGoogle Scholar
  135. 135.
    Weiss HD, Walker MD, Wiernik PH: Neurotoxicity of commonly used antineoplastic agents. N Engl J Med 291:75–81 and 127–133, 1974.PubMedGoogle Scholar
  136. 136.
    Land VJ, Sutow WW, Fernbach DJ, et al.: Toxicity of L-asparaginase in children with advanced leukemia. Cancer 30:339–347, 1972.PubMedGoogle Scholar
  137. 137.
    Lessner HE, Valenstein S, Kaplan R, et al.: Phase II study of L-asparaginase in the treatment of pancreatic carcinoma. Cancer Treat Rep 64:1359–1361, 1980.PubMedGoogle Scholar
  138. 138.
    Moure JMB, Whitecar JP, Bodey GP: Electroencephalogram changes secondary to asparaginase. Arch Neurol 23:365–368, 1970.PubMedGoogle Scholar
  139. 139.
    Ohnuma T, Holland JF, Freeman A, Sinks LF: Biochemical and pharmacological studies with asparaginase in man. Cancer Res 30:2297–2305, 1970.PubMedGoogle Scholar
  140. 140.
    Riccardi R, Holcenberg J, Glaubiger D, Po-plack D: L-asparaginase pharmacokinetics and L-asparagine in the cerebrospinal fluid. Proc Am Assoc Cancer Res 21:336, 1980.Google Scholar
  141. 141.
    Cairo MS, Lazarus K, Gilmore RL, Baehner RL: Intracranial hemorrhage and focal seizures secondary to use of L-asparaginase during induction therapy of acute lymphocytic leukemia. J Pediatr 97:829–833, 1980.PubMedGoogle Scholar
  142. 142.
    Priest JR, Ramsay NK, Latchaw RE, et al.: Thrombotic and hemorrhagic strokes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer 46:1548–1554, 1980.PubMedGoogle Scholar
  143. 143.
    Moertel CG, Reitemeier RJ, Bolton CF, Shorter RG: Cerebellar ataxia associated with fluorinated pyrimidine therapy. Cancer Chemother Rep 41:15–18, 1964.PubMedGoogle Scholar
  144. 144.
    Riehl JL, Brown WJ: Acute cerebellar syndrome secondary to 5-fluorouracil therapy. Neurology (Minneap) 14:254, 1964.Google Scholar
  145. 145.
    Gottlieb J A, Luce JK: Cerebellar ataxia with weekly 5-fluorouracil administration. Lancet 1:138–139, 1971.PubMedGoogle Scholar
  146. 146.
    Boileau G, Piro AJ, Lahiri SR, et al.: Cerebellar ataxia during 5-fluorouracil (NSC-19893) therapy. Cancer Chemother Rep 55:595–598, 1971.PubMedGoogle Scholar
  147. 147.
    Koenig H. Patel A: The acute cerebellar syndrome in 5-fluorouracil chemotherapy: a manifestation of fluoroacetate intoxication. Neurology (Minneap) 20:416, 1970.Google Scholar
  148. 148.
    Lee IP, Lucier GW: The potentiation of barbiturate-induced narcosis by procarbazine. J Pharmacol Exp Ther 196:586–593, 1976.PubMedGoogle Scholar
  149. 149.
    De Fronzo RA, Braine H, Colvin OM, Davis PJ: Water intoxification in man after cyclophosphamide therapy. Ann Intern Med 78:861–869, 1973.Google Scholar
  150. 150.
    Steele TH, Serpick AA, Block JB: Antidiuretic response to cyclophosphamide in man. J Pharmacol Exp Ther 185:245–253, 1973.PubMedGoogle Scholar
  151. 151.
    Grossman L, Baker MA, et al.: Central nervous system toxicity of high-dose cytosine arabino-side. Med Pediatr Oncol 11:246–250, 1983.PubMedGoogle Scholar
  152. 152.
    Levi J A, Wiernik PH: A comparative clinical trial of 5 azacytidine and guanazole in previously treated adults with acute nonlymphocytic leukemia. Cancer 38:36–41, 1976.PubMedGoogle Scholar
  153. 153.
    Saiki JH, Bodey GP, Hewlett JS, et al.: Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia. Cancer 47:1739–1742, 1981.PubMedGoogle Scholar
  154. 154.
    Rubinstein LJ, Herman MM, Long TG, Wilbur JR: Disseminated necrotizing leukoencephalo-pathy: a complication of treated central nervous system leukemia and lymphoma. Cancer 35: 291–305, 1975.PubMedGoogle Scholar
  155. 155.
    Kay HEM, Knapton PJ, O’Sullivan JP, et al.: Encephalopathy in acute leukemia associated with methotrexate therapy. Arch Dis Child 47:344–354, 1972.PubMedGoogle Scholar
  156. 156.
    Hendin B, De Vivo DC, Torack R, et al.: Parenchymatous degeneration of the central nervous system in childhood leukemia. Cancer 33:468–482, 1974.PubMedGoogle Scholar
  157. 157.
    Price RA, Jamieson PA: The central nervous system in childhood leukemia. II. Subacute leucoencephalopathy. Cancer 35:306–318, 1975.PubMedGoogle Scholar
  158. 158.
    Liu HM, Maurer HS, Vongsvivut S, Conway JJ: Methotrexate encephalopathy, a neuropathology study. Hum Pathol 9:635–648, 1978.PubMedGoogle Scholar
  159. 159.
    Meadows AT, Evans AE: Effects of chemotherapy on the central nervous system. Cancer 37:1079–1085, 1976.PubMedGoogle Scholar
  160. 160.
    Flament-Durand J, Ketelbant-Balasse P, Maurus R, et al.: Intracerebral calcifications appearing during the course of acute lymphocytic leukemia treated with methotrexate and x-rays. Cancer 35:319–325, 1975.PubMedGoogle Scholar
  161. 161.
    Peylan-Ramu N, Poplack DG, Pizzo PA, et al.: Abnormal CT scans of the brain in asymptomatic children with acute lymphocytic leukemia after prophylactic treatment of the central nervous system with radiation and intrathecal chemotherapy. N Engl J Med 298:815–818, 1978.PubMedGoogle Scholar
  162. 162.
    McIntosh S, Fischer DB, Rothman SG, et al.: Intracranial calcifications in childhood leukemia: an association with systemic chemotherapy. J Pediatr 91:909–913, 1977.PubMedGoogle Scholar
  163. 163.
    Aur RJA, Simone JV, Verzosa MS, et al.: Childhood lymphocytic leukemia: study VIII. Cancer 42:2123–2134, 1978.PubMedGoogle Scholar
  164. 164.
    Bleyer WA, Griffin TW: White matter necrosis, mineralizing microangiopathy, and intellectual abilities in survivors of childhood leukemia: associations with central nervous system irradiation and methotrexate therapy. In: Gilbert HA, Kagan AR (eds) Radiation damage to the nervous system. New York, Raven, 1980, pp 155–174.Google Scholar
  165. 165.
    Allen JC, Rosen G, Mehta BM, Horten B: Leukoencephalopathy following high-dose IV methotrexate chemotherapy with leucovorin rescue. Cancer Treat Rep 64:1261–1273, 1980.PubMedGoogle Scholar
  166. 166.
    Oliff A, Bleyer WA, Poplack DG: Acute encephalopathy after initiation of cranial irradiation for meningeal leukemia. Lancet 2:13–15, 1978.PubMedGoogle Scholar
  167. 167.
    McIntosh S, Klatskin EH, O’Brien RT, et al.: Chronic neurologic disturbance in childhood leukemia. Cancer 37:853–857, 1976.PubMedGoogle Scholar
  168. 168.
    Ch’ien CT, Aur RJA, Stagner S, et al.: Long-term neurological implications of somnolence syndrome in children with acute lymphocytic leukemia. Ann Neurol 8:273–277, 1980.PubMedGoogle Scholar
  169. 169.
    Dichiro G, Arimitsu T, Brooks RA, et al.: Computed tomography profiles of periventricular hypodensity in hydrocephalus and leukoencephalopathy. Radiology 130:661–666, 1979.Google Scholar
  170. 170.
    Gangji D, Reaman GH, Cohen SR, et al.: Leukoencephalopathy and elevated levels of myelin basic protein in the cerebrospinal fluid of patients with acute lymphoblastic leukemia. N Engl J Med 303:19–21, 1980.PubMedGoogle Scholar
  171. 171.
    Price RA, Birdwell DA: The central nervous system in childhood leukemia. III. Mineralizing microangiopathy and dystrophic calcification. Cancer 42:717–728, 1978.PubMedGoogle Scholar
  172. 172.
    Burger PC, Kamenar E, Schold SC, Fay JW, Phillips GL, Herzig GP: Encephalomyelopathy following high-dose BCNU therapy. Cancer 48:1318–1327, 1981.Google Scholar
  173. 173.
    Crosley CJ, Rorke LB, Evans A, Nigrom: Central nervous system lesions in childhood leukemia. Neurology 28:678–685, 1978.PubMedGoogle Scholar
  174. 174.
    Mcintosh S, Aspnes GT: Encephalopathy following CNS prophylaxis in childhood lymphoblastic leukemia. Pediatrics 52:612–615, 1973.PubMedGoogle Scholar
  175. 175.
    Freeman JE, Johnston PG, Voke JM: Somnolence after prophylactic cranial irradiation in children with acute lymphoblastic leukemia. Br Med J 4:523–525, 1973.PubMedGoogle Scholar
  176. 176.
    Garwicz S, Aronson S, Elmqvist D, et al.: Post-irradiation syndrome and EEG findings in children with acute lymphoblastic leukemia. Acta Pediatr Scand 64:399–403, 1975.Google Scholar
  177. 177.
    Parker D, Malpas JS, Sandland R, et al.: Outlook following “somnolence syndrome” after prophylactic cranial irradiation. Br Med J 1:554–559, 1978.PubMedGoogle Scholar
  178. 178.
    Demeocq F, Malpuech G, Raynaud EJ, et al.: Elevation of β2-microglobulin in cerebrospinal fluid after irradiation of the central nervous system. E Engl J Med 304:1366, 1981.Google Scholar
  179. 179.
    Breuer AC, Blank NK, Schoene WC: Multifocal pontine lesions in cancer patients treated with chemotherapy and CNS radiotherapy. Cancer 41:2112–2120, 1978.PubMedGoogle Scholar
  180. 180.
    Griffin TW, Rasey JS, Bleyer WA: The effect of photon irradiation on blood—brain barrier permeability to methotrexate in mice. Cancer 40:1109–1111, 1977.PubMedGoogle Scholar
  181. 181.
    Levin VA, Edwards MS, Byrd A: Quantitative observations on the acute effects of x-irradiation on brain capillary permeability. I. Int J Radiat Oncol Biol Phys 5:1627–1631, 1979.PubMedGoogle Scholar
  182. 182.
    Edwards MS, Levin VA, Byrd A: Quantitative observations on the acute effects of x-irradiation on brain capillary permeability. II. Int J Radiat Oncol Biol Phys 5:1633–1635, 1979.PubMedGoogle Scholar
  183. 183.
    Abelson HT: Methotrexate and central nervous system toxicity. Cancer Treat Rep 62:1999–2001, 1978.PubMedGoogle Scholar
  184. 184.
    Bleyer WA: Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep 61:1419–1425, 1977.PubMedGoogle Scholar
  185. 185.
    Rosenthal S, Kaufman S: Vincristine neurotoxicity. Ann Intern Med 80:733–737, 1974.PubMedGoogle Scholar
  186. 186.
    Sandler SG, Tobin W, Henderson ES: Vin-cristine-induced neuropathy: a clinical study of fifty leukemic patients. Neurology (Minneap) 19:367–374, 1969.Google Scholar
  187. 187.
    Holland JF, Scharlav C, Gailani S, et al.: Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res 33: 1258–1264, 1973.PubMedGoogle Scholar
  188. 188.
    Von Hoff DD, Schilsky R, Reichert CM, et al.: Toxic effects of cis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep 63:1527–1531, 1979.Google Scholar
  189. 189.
    Ostrow S, Hahn D, Wiernik PH, Richards RD: Ophthalmologic toxicity after cis-dichlorodiammineplatinum (II) therapy. Cancer Treat Rep 62:1591–1594, 1978.PubMedGoogle Scholar
  190. 190.
    Berman IJ, Mann MP: Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer 45:764–766, 1980.PubMedGoogle Scholar
  191. 191.
    Stewart D, Wallace S, Leavens M, et al.: Phase I study of intracarotid cis-diamminedichloro-platinum in patients with intracerebral tumors. Proc Am Assoc Cancer Res 22:189, 1981.Google Scholar
  192. 192.
    Law IP, Blom J: Adult acute leukemia: frequency of central nervous system involvement in long term survivors. Cancer 40:1304–1306, 1977.PubMedGoogle Scholar
  193. 193.
    Jacobs AD, Gale RP: Recent advances in the biology and treatment of acute lymphoblastic leukemia in adults. N Engl J Med 311:1219–1231, 1984.PubMedGoogle Scholar
  194. 194.
    Schweinle JE, Alperin JB: Central nervous system recurrence ten years after remission of acute lymphoblastic leukemia. Cancer 45:16–18, 1980.PubMedGoogle Scholar
  195. 195.
    Levitt LJ, Dawson OM, Rosenthal DS, Moloney WC: CNS involvement in the non-Hodgkin’s lymphomas. Cancer 45:545–552, 1980.PubMedGoogle Scholar
  196. 196.
    Aisner J, Aisner SC, Ostrow S, Govindan S, Mummert K, Wiernik P: Meningeal carcinomatosis from small cell carcinoma of the lung: consequence of improved survival. Acta Cytol 23:292–296, 1979.PubMedGoogle Scholar
  197. 197.
    Aroney RS, Dalley DN, Chan WK, Bell DR, Levi JA: Meningeal carcinomatosis in small cell carcinoma of the lung. Am J Med 71:26–32, 1981.PubMedGoogle Scholar
  198. 198.
    Aisner J, Ostrow S, Govindan S, Wiernik PH: Leptomeningeal carcinomatosis in small cell carcinoma of the lung. Med Pediatr Oncol 9:47–59, 1981.PubMedGoogle Scholar
  199. 199.
    Price RA, Johnson WW: The central nervous system in childhood leukemia. I. The arachnoid. Cancer 31:520–533, 1973.PubMedGoogle Scholar
  200. 200.
    Thomas LB: Pathology of leukemia in the brain and meninges: postmortem studies of patients with acute leukemia and of mice given inoculations of L1210 leukemia. Cancer Res 25:1555–1571, 1965.PubMedGoogle Scholar
  201. 201.
    Huei-Mei Kuo A, Yataganas X, Galicich JH, Freid J, Clarkson BD: Proliferative kinetics of central nervous system (CNS) leukemia. Cancer 36:232–239, 1975.Google Scholar
  202. 202.
    Tsuchiya J, Moteki M, Shimano S, et al.: Proliferative kinetics of the leukemic cells in meningeal leukemia. Cancer 42:1255–1262, 1978.PubMedGoogle Scholar
  203. 203.
    Greydanus DE, Burgert EO, Gilchrist GS: Hypothalamic syndrome in children with acute lymphocytic leukemia. Mayo Clin Proc 53: 217–220, 1978.PubMedGoogle Scholar
  204. 204.
    Blade J, Gaston F, Montserrat E, et al.: Spinal subarachnoid hematoma after lumbar puncture causing reversible paraplegia in acute leukemia. J Neurosurg 58:438–439, 1983.PubMedGoogle Scholar
  205. 205.
    Glass JP, Melamed M, Chernik NL, Posner JB: Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29:1369–1375, 1979.PubMedGoogle Scholar
  206. 206.
    Rienhoff HY Jr: Neoplastic meningitis. Johns Hopkins Med J 151:59–64, 1982.Google Scholar
  207. 207.
    Olson ME, Chernik NL, Posner JB: Infiltration of the leptomeninges by systemic cancer: a clinical and pathologic study. Arch Neurol 30:122–137, 1974.PubMedGoogle Scholar
  208. 208.
    Little JP, Dale AJ, Okazaki H: Meningeal carcinomatosis. Arch Neurol 30:138–143, 1974.PubMedGoogle Scholar
  209. 209.
    Evans DIK, O’Rourke C, Jones PM: The cerebrospinal fluid in acute leukaemia of childhood: studies with the cytocentrifuge. J Clin Pathol 27:226–230, 1974.PubMedGoogle Scholar
  210. 210.
    Drewinko B, Sullivan MP, Martin T: Use of the cytocentrifuge in the diagnosis of meningeal leukemia. Cancer 31:1331–1336, 1973.PubMedGoogle Scholar
  211. 211.
    Komp DM, Cox BJ: Cytocentrifugation in the management of central nervous system leukemia. J Pediatr 81:992–994, 1972.PubMedGoogle Scholar
  212. 212.
    Ducos R, Donoso J, Weickhardt U, Vietti TJ: Sedimentation versus cytocentrifugation in the cytologic study of craniospinal fluid. Cancer 43:1479–1482, 1979.PubMedGoogle Scholar
  213. 213.
    Murray JJ, Greco FA, Wolff SN, Hainsworth JD: Neoplastic meningitis: marked variations of cerebrospinal fluid composition in the absence of extradural block. Am J Med 75:289–294, 1983.PubMedGoogle Scholar
  214. 214.
    Bradstock KF, Papageorgiou ES, Janossy G: Diagnosis of meningeal involvement in patients with acute lymphoblastic leukemia: immunofluorescence for terminal transferase. Cancer 47:2478–2481, 1981.PubMedGoogle Scholar
  215. 215.
    Mavligit GM, Stuckey SE, Cabanillas FF, Keating MJ, Tourtellotte WW, Schold SC, Freireich EJ: Diagnosis of leukemia or lymphoma in the central nervous system by beta2-microglobulin determination. N Engl J Med 303:718–722, 1980.Google Scholar
  216. 216.
    Ratcheson RA, Ommaya AK: Experience with the subcutaneous cerebrospinal-fluid reservoir. N Engl J Med 279:1025–1031, 1968.PubMedGoogle Scholar
  217. 217.
    Bleyer WA, Poplack DG, Simon RM: “Concentration x time” methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 51:835–842, 1978.PubMedGoogle Scholar
  218. 218.
    Trump DL, Grossman ST, Thompson G, Murray K, Wharam M: Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate. Cancer Treat Rep 66:1549–1551, 1982.PubMedGoogle Scholar
  219. 219.
    Gutin PH, Weiss HD, Wiernik PH, Walker MD: Intrathecal N, N’, N’ triethylene-thiophosphoramide thio-tepa (NSC 6396) in the treatment of malignant meningeal disease. Cancer 38:1471–1475, 1976.PubMedGoogle Scholar
  220. 220.
    Skarin AT, Zuckerman KS, Pitman SW, Rosenthal DS, Moloney W, Frei E III, Canellos GP: High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin’s lymphoma including CNS involvement. Blood 50: 1039–1047, 1977.PubMedGoogle Scholar
  221. 221.
    Frei E III, Blum RH, Pitman SW, Kirkwood JM, Henderson IC, Skarin AT, Mayer RJ, Bast RC, Garnick MB, Parker LM, Canellos GP: High-dose methotrexate with leukovorin rescue. Am J Med 68:370–376, 1980.PubMedGoogle Scholar
  222. 222.
    Frick J, Ritch PS, Hansen RM, Anderson T: Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside. J Clin Oncol 2:365–368, 1984.PubMedGoogle Scholar
  223. 223.
    Freeman AI, Weinberg V, Brecher ML, Jones B, Glicksman AS, et al.: Comparison of intermediate-dose methotrexate with cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children. N Engl J Med 308:477–484, 1983.PubMedGoogle Scholar
  224. 224.
    Stewart DJ, Keating MJ, Mredie KB, Smith TL, Youness E, Murphy SG, Bodey GP, Freireich EJ: Natural history of central nervous system acute leukemia in adults. Cancer 47:184–196, 1981.PubMedGoogle Scholar
  225. 225.
    Shapiro WR, Posner JB, Ushio Y, Chernik NL, Young DF: Treatment of meningeal neoplasms. Cancer Treat Rep 61:733–743, 1977.PubMedGoogle Scholar
  226. 226.
    Theodore WH, Gendelman S: Meningeal carcinomatosis. Arch Neurol 38:696–699, 1981.PubMedGoogle Scholar
  227. 227.
    Yap HY, Yap BS, Rasmussen S, Levens ME, Hortobagyi GN, Blumenschein GR: Treatment for meningeal carcinomatosis in breast cancer. Cancer 49:219–222, 1982.Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1986

Authors and Affiliations

  • N. Simon Tchekmedyian
  • Richard S. Kaplan

There are no affiliations available

Personalised recommendations